1092 related articles for article (PubMed ID: 34319141)
1. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
4.
Chen T; Xu W; Yu K; Zeng W; Xu C; Cao J; Zhou T
Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
[No Abstract] [Full Text] [Related]
5. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
6. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
7. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Meschiari M; Franconi I; Bacca E; Bianco V; Orlando G; Cuomo G; Bedini A; Mussini C
Infection; 2021 Jun; 49(3):549-553. PubMed ID: 33074365
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
10. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
[TBL] [Abstract][Full Text] [Related]
11. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
12. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
[TBL] [Abstract][Full Text] [Related]
13.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
15. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
[TBL] [Abstract][Full Text] [Related]
19.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]